尿激酶静脉溶栓治疗急性心肌梗塞疗效相关因素对比研究

Relative factors study on intravenous thrombolytic therapy in acute myocardiac infarction

对163例尿激酶静脉溶栓治疗急性心肌梗塞（AMI）临床疗效、安全性从不同分层角度进行比较，结果显示：总再通率65.6％，出血率11.0％，5周内死亡率9．2％，起病距溶栓6h内再通率明显高于6b以后（P＜0．01），且死亡率低。不同年龄组6h以内再通率无显著差异（P＞0．05），≥70岁组6h后再通率低于其他年龄组，有显著性差异（P＜0．01）。轻度出血率及死亡率各年龄组无显著差异（P＞0．05）。女性组与男性组比较再通率低、死亡率高、有显著性差异（P＜0．05）。尿激酶剂量以150万u左右为宜。

Analysin on our 163 cases, the reliable degree and clinical curatire effect of urokinase intravenous thrombolytic to cure acute myocardiac infarction is that the total reperfusion rate amounts to 65. 6 percent, bleeding rate 11 .0 parcent death rate (within 5 weeks)9.2 percent. When UK was given within 6 hours after AMI onset, the reperfusion rate is clearly higher than 6 hours later (P < 0.01) and the death rate is lower. When UK was given within 6 hours, there is no clear distinction in reperfusion rate amongy groups of different age (P > 0. 05 ). However, compared with other groups,to the over 70 year old groups, the reperfusion rate is lower when UK was given 6 hours later and the distinction is very clear as well (P < 0.01). As to the bleeding rate of light degree and death rate, there is no clear distinction among all the groups (P > 0.05). The female comparing with the male, its reperfusion the is lower while the death rate is higher and there exiots clear distinction (P < 0. 05). The best of the dosage of urokinase is 1 .5 million units or so.